Board of Directors


Nassim Usman, Ph.D. – Venture Partner, Morgenthaler Ventures

Dr. Nassim Usman served as Chief Executive Officer and a member of the board of directors of Catalyst Biosciences from 2006 until 2015. Since the merger with Targacept in 2015, Dr. Usman has served as Catalyst’s President and Chief Executive Officer. Dr. Usman joined Catalyst from Morgenthaler Ventures, where he is currently a Venture Partner. Prior to joining Morgenthaler in 2005, from 2004 to 2005, he was Senior Vice President and Chief Operating Officer at Sirna Therapeutics Inc., which was subsequently acquired by Merck, and held various R&D positions at both Sirna and Ribozyme Pharmaceuticals, including Vice President of R&D and Chief Science Officer, from 1992 to 2004. Dr. Usman has overseen the entry of several drugs into clinical development, completion of multiple licensing deals with pharmaceutical and biotechnology companies and raised capital in both private and public financings.

Dr. Usman was an NIH Fogarty and NSERC Postdoctoral Fellow and Scientist in the Departments of Biology and Chemistry at the Massachusetts Institute of Technology from 1987 to 1992. He has authored more than 70 scientific articles and is the named inventor in 130 issued patents and patent applications.

In addition to serving on Mosaic’s board, Dr. Usman also serves on the boards of directors of Principia Biopharma. He received his B.Sc. and Ph.D. in Organic Chemistry from McGill University. In his doctoral dissertation, he developed a method for the solid-phase synthesis of RNA that is widely used in science and in a marketed RNA product.


Mark Lupa, Ph.D. – Managing Director of High Country Ventures

With a Masters in Bioengineering and a PhD in Pharmacology, Dr. Lupa has a unique pedigree that includes 15 years medical research experience and being a Founder, former CEO, and CFO of Tabernash Brewing Company.  In addition to his work with Mosaic Mark serves on several boards, including LeftHand/Tabernash, Oberon, TheraTogs, Surefire Medical, and Endoshape.

Gus Lawlor – Managing Director of HealthCare Ventures

Gus Lawlor has been a Managing Director of HealthCare Ventures since 2000.  He was previously Chief Operating Officer of LeukoSite, Inc., a HealthCare Ventures III, IV, and V company.  Before joining LeukoSite, he was Chief Financial Officer and Vice President of Corporate Development for Alpha-Beta Technology.  He held similar positions at BioSurface Technology and Armstrong Pharmaceuticals.  He received a Master’s degree in Public and Private Management from Yale University.


Marty Stanton, Ph.D. – CEO of Mosaic Biosciences